Kymera Therapeutics, Inc.
KYMR
Rankning i aktier
#2161
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Aktiekurs
$112.11
Marknadsvärde
$9.22B
Förändring (1 dag)
-0.47%
Förändring (1 år)
100.91%
Land
US
Handel Kymera Therapeutics, Inc. (KYMR)
Kategori
Healthcare
Aktiekurshistorik för Kymera Therapeutics, Inc. (KYMR)
Högsta slutkurs: $109.26 den 2026-10-01
Lägsta slutkurs: $31.67 den 2020-08-01
Lägsta slutkurs: $31.67 den 2020-08-01
Aktiekurshistorik för Kymera Therapeutics, Inc. från 2020 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2026 (TTM) | 12.16% |
| 2025 | 87.59% |
| 2024 | 77.01% |
| 2023 | -11.39% |
| 2022 | -52.05% |
| 2021 | -12.80% |
| 2020 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $537.25 | 25.98% |
US
|
|
| $195.62 | 628.57% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $881.90 | 8.32% |
NL
|
